Research programme: neuraminidase inhibitors - Aviragen Therapeutics/Daiichi Sankyo

Drug Profile

Research programme: neuraminidase inhibitors - Aviragen Therapeutics/Daiichi Sankyo

Alternative Names: BTA929; BTA938; BTA978

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biota Holdings
  • Developer Aviragen Therapeutics; Daiichi Sankyo Company
  • Class Guanidines
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in Australia (Inhalation)
  • 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics
  • 08 Nov 2012 Biota Holdings has merged with Nabi Biopharmaceuticals to form Biota Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top